Osanetant

Osanetant
Clinical data
ATC code	none;
Identifiers
	IUPAC name N-(1-{3-[(3R)-1-benzoyl-3-(3,4-dichlorophenyl)piperidin-3-yl]propyl}-4-phenylpiperidin-4-yl]-N-methylacetamide;
CAS Number	160492-56-8 ;
PubChem CID	219077;
IUPHAR/BPS	2110;
ChemSpider	189901 ;
UNII	K7G81N94DT;
ChEMBL	CHEMBL346178 ;
ECHA InfoCard	100.233.307
Chemical and physical data
Formula	C35H41Cl2N3O2
Molar mass	606.625 g/mol
3D model (JSmol)	Interactive image;
	SMILES CC(=O)N(C)C1(CCN(CC1)CCC[C@@]2(CCCN(C2)C(=O)C3=CC=CC=C3)C4=CC(=C(C=C4)Cl)Cl)C5=CC=CC=C5;
	InChI InChI=1S/C35H41Cl2N3O2/c1-27(41)38(2)35(29-13-7-4-8-14-29)19-23-39(24-20-35)21-9-17-34(30-15-16-31(36)32(37)25-30)18-10-22-40(26-34)33(42)28-11-5-3-6-12-28/h3-8,11-16,25H,9-10,17-24,26H2,1-2H3/t34-/m0/s1 ; Key:DZOJBGLFWINFBF-UMSFTDKQSA-N ;
(what is this?) (verify)

Osanetant (SR-142,801) was a neurokinin 3 receptor antagonist developed by Sanofi-Synthélabo, which was being researched for the treatment of schizophrenia, but was discontinued.^[1]^[2] It was the first non-peptide NK₃ antagonist developed in the mid-1990s,^[3]^[4] Other potential applications for osanetant is in the treatment of drug addiction, as it has been found to block the effects of cocaine in animal models.^[5]^[6]

References

↑ "osanetant Sanofi-Aventis discontinued, France". Highbeam.
↑ Kamali, F (July 2001). "Osanetant Sanofi-Synthélabo". Current Opinion in Investigational Drugs. 2 (7): 950–6. PMID 11757797.
↑ Emonds-Alt, X; Bichon, D; Ducoux, JP; Heaulme, M; Miloux, B; Poncelet, M; Proietto, V; Van Broeck, D; et al. (1995). "SR 142801, the first potent non-peptide antagonist of the tachykinin NK3 receptor". Life Sciences. 56 (1): PL27–32. doi:10.1016/0024-3205(94)00413-M. PMID 7830490.
↑ Quartara L, Altamura M (August 2006). "Tachykinin receptors antagonists: from research to clinic". Current Drug Targets. 7 (8): 975–92. doi:10.2174/138945006778019381. PMID 16918326. Retrieved 2011-04-14.
↑ Desouzasilva, M; Mellojr, E; Muller, C; Jocham, G; Maior, R; Huston, J; Tomaz, C; Barros, M (May 2006). "The tachykinin NK3 receptor antagonist SR142801 blocks the behavioral effects of cocaine in marmoset monkeys". European Journal of Pharmacology. 536 (3): 269–78. doi:10.1016/j.ejphar.2006.03.010. PMID 16603151.
↑ Jocham, Gerhard; Lezoch, Katharina; Müller, Christian P.; Kart-Teke, Emriye; Huston, Joseph P.; De Souza Silva, M. AngéLica (September 2006). "Neurokinin receptor antagonism attenuates cocaine's behavioural activating effects yet potentiates its dopamine-enhancing action in the nucleus accumbens core". European Journal of Neuroscience. 24 (6): 1721–32. doi:10.1111/j.1460-9568.2006.05041.x. PMID 17004936.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] "osanetant Sanofi-Aventis discontinued, France". Highbeam.

[2] Kamali, F (July 2001). "Osanetant Sanofi-Synthélabo". Current Opinion in Investigational Drugs. 2 (7): 950–6. PMID 11757797.

[3] Emonds-Alt, X; Bichon, D; Ducoux, JP; Heaulme, M; Miloux, B; Poncelet, M; Proietto, V; Van Broeck, D; et al. (1995). "SR 142801, the first potent non-peptide antagonist of the tachykinin NK3 receptor". Life Sciences. 56 (1): PL27–32. doi:10.1016/0024-3205(94)00413-M. PMID 7830490.

[pmid16918326-4] Quartara L, Altamura M (August 2006). "Tachykinin receptors antagonists: from research to clinic". Current Drug Targets. 7 (8): 975–92. doi:10.2174/138945006778019381. PMID 16918326. Retrieved 2011-04-14.

[5] Desouzasilva, M; Mellojr, E; Muller, C; Jocham, G; Maior, R; Huston, J; Tomaz, C; Barros, M (May 2006). "The tachykinin NK3 receptor antagonist SR142801 blocks the behavioral effects of cocaine in marmoset monkeys". European Journal of Pharmacology. 536 (3): 269–78. doi:10.1016/j.ejphar.2006.03.010. PMID 16603151.

[6] Jocham, Gerhard; Lezoch, Katharina; Müller, Christian P.; Kart-Teke, Emriye; Huston, Joseph P.; De Souza Silva, M. AngéLica (September 2006). "Neurokinin receptor antagonism attenuates cocaine's behavioural activating effects yet potentiates its dopamine-enhancing action in the nucleus accumbens core". European Journal of Neuroscience. 24 (6): 1721–32. doi:10.1111/j.1460-9568.2006.05041.x. PMID 17004936.

Neurokinin receptor modulators
NK₁	Agonists: Substance P Antagonists: Aprepitant Befetupitant Burapitant Casopitant CI-1021 CP-96345 CP-99994 CP-122721 Dapitant Ezlopitant Figopitant FK-888 Fosaprepitant Fosnetupitant GR-203040 GW-597599 HSP-117 L-733,060 L-741,671 L-743,310 L-758,298 Lanepitant LY-306740 Maropitant Netupitant NKP-608 Nolpitantium besilate Orvepitant Rolapitant RP-67580 SDZ NKT 343 Serlopitant T-2328 Telmapitant Tradipitant Vestipitant Vofopitant
NK₂	Agonists: Neurokinin A Antagonists: GR-159897 Ibodutant Nepadutant Saredutant
NK₃	Agonists: Neurokinin B Senktide Antagonists: Fezolinetant (ESN-364) Osanetant (SR-142,801) Pavinetant (MLE-4901, AZD-2624, AZD-4901) SB-218,795 SB-222,200 Talnetant (SB-223,412)
See also: Receptor/signaling modulators • Signaling peptide/protein receptor modulators

Clinical data

ATC code	none
Identifiers
IUPAC name N-(1-{3-[(3R)-1-benzoyl-3-(3,4-dichlorophenyl)piperidin-3-yl]propyl}-4-phenylpiperidin-4-yl]-N-methylacetamide
CAS Number	160492-56-8^Y
PubChem CID	219077
IUPHAR/BPS	2110
ChemSpider	189901^N
UNII	K7G81N94DT
ChEMBL	CHEMBL346178^N
ECHA InfoCard	100.233.307
Chemical and physical data
Formula	C₃₅H₄₁Cl₂N₃O₂
Molar mass	606.625 g/mol
3D model (JSmol)	Interactive image
SMILES CC(=O)N(C)C1(CCN(CC1)CCC[C@@]2(CCCN(C2)C(=O)C3=CC=CC=C3)C4=CC(=C(C=C4)Cl)Cl)C5=CC=CC=C5
InChI InChI=1S/C35H41Cl2N3O2/c1-27(41)38(2)35(29-13-7-4-8-14-29)19-23-39(24-20-35)21-9-17-34(30-15-16-31(36)32(37)25-30)18-10-22-40(26-34)33(42)28-11-5-3-6-12-28/h3-8,11-16,25H,9-10,17-24,26H2,1-2H3/t34-/m0/s1^N Key:DZOJBGLFWINFBF-UMSFTDKQSA-N^N
^NY (what is this?) (verify)

Osanetant

See also

References